Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irbesartan is an angiotensin II receptor blocker (ARB) used primarily to treat high blood pressure (hypertension) and to protect kidney function in people with type 2 diabetes and nephropathy. It works by selectively blocking the AT1 subtype of angiotensin II receptors in tissues such as vascular smooth muscle and the adrenal gland. This blockade prevents angiotensin II from causing vasoconstriction and aldosterone secretion, resulting in relaxation of blood vessels and reduced blood pressure. Irbesartan has a much higher affinity for the AT1 receptor than for the AT2 receptor (over 8500-fold). It is taken orally once daily due to its long duration of action. Developed by Sanofi.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on irbesartan.